FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPE FELIPE

Their core work

CIPF is a biomedical research centre in Valencia, Spain, specializing in polymer-based nanomedicines, chemical biology screening, and regenerative medicine. Their core competence lies in designing advanced biomaterials — from polymer nanoparticles for cancer treatment to biohybrid scaffolds for spinal cord repair. They operate at the intersection of chemistry and biology, translating molecular-level discoveries into therapeutic applications, particularly in oncology, metabolic disease, and tissue regeneration.

What they specialise in

How they've shifted over time

CIPF's early H2020 work (2015–2018) centred on fundamental biomedical questions — brown fat biology, obesity mechanisms, and protein complex biochemistry. From 2019 onward, their focus shifted decisively toward applied biomaterials and translational medicine: spinal cord regeneration scaffolds, chemical biology infrastructure, and glycopolymer-based tools. This trajectory shows a centre moving from basic research toward platform technologies with clearer clinical and industrial applications.

CIPF is evolving from a fundamental biomedical lab into a translational biomaterials and drug discovery platform, making them increasingly relevant for industry partnerships in therapeutics development.

How they like to work

CIPF operates primarily as a participant (5 of 7 projects) but has proven coordinator capability, having led two projects including their largest (MyNano, EUR 1.7M). With 56 unique partners across 22 countries, they maintain a broad and diverse network rather than relying on repeat collaborators. This suggests an adaptable partner that integrates well into varied consortia and brings specialist biomaterials expertise without requiring a leadership role.

CIPF has collaborated with 56 distinct partners across 22 countries, indicating a well-connected European network. Their participation in pan-European infrastructure projects like EU-OPENSCREEN-DRIVE further extends their reach across the continent's chemical biology community.

What sets them apart

CIPF combines polymer chemistry, biomaterials engineering, and biomedical research under one roof — a rare mix that lets them design therapeutic materials from molecule to application. Their dual experience as both a screening infrastructure node (EU-OPENSCREEN) and a nanomedicine developer gives them unusual versatility. For consortium builders, they offer a Spanish partner with strong materials-biology integration and the flexibility to serve as either coordinator or specialist contributor.

Highlights from their portfolio

• MyNano
  Largest project (EUR 1.7M) and coordinator role — designed personalised polymer nanomedicines for advanced breast cancer, demonstrating CIPF's capacity to lead ambitious translational research.
• RISEUP
  Combines electropulse technology with biohybrid scaffolds and stem cell transplantation for spinal cord injury — an unusually interdisciplinary approach bridging bioelectronics and regenerative medicine.
• EU-OPENSCREEN-DRIVE
  Positions CIPF within Europe's chemical biology screening infrastructure, giving them access to compound libraries and medicinal chemistry networks beyond their own walls.